- $13.54m
- -$2.16m
- 12
- 32
- 91
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -147.03% | ||
| Return on Equity | -91.37% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.5 | 0.5 | 0.5 | 0.5 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Directors
- Jeffrey Church CFO (64)
- Khursheed Anwer EVP (61)
- Nicholas Borys EVP (61)
- Michael Tardugno DRC (70)
- Stacy Lindborg DRC (50)
- Christine Pellizzari DRC (53)
- Donald Braun IND (71)
- Augustine Chow IND (68)
- Frederick Fritz IND (70)
- Robert Hooper IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 17th, 2000
- Public Since
- October 27th, 1993
- No. of Shareholders
- 28,000
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 9,399,789
- Address
- 997 Lenox Dr Ste 100, LAWRENCEVILLE, 08648
- Web
- https://imunon.com/
- Phone
- +1 6098969100
- Contact
- Jeffrey Church
- Auditors
- WithumSmith Brown PC
Upcoming Events for IMNN
Imunon Inc Annual Shareholders Meeting
Imunon Inc Annual Shareholders Meeting
Q2 2024 Imunon Inc Earnings Release
Similar to IMNN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Imunon share price?
As of Today at 19:11 UTC, shares in Imunon are trading at $1.44. This share price information is delayed by 15 minutes.
How has the Imunon share price performed this year?
Shares in Imunon last closed at $1.44 and the price had moved by +25.22% over the past 365 days. In terms of relative price strength the Imunon share price has outperformed the S&P500 Index by +2.37% over the past year.
What are the analyst and broker recommendations for Imunon?
The overall consensus recommendation for Imunon is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Imunon dividend yield?
Imunon does not currently pay a dividend.
Does Imunon pay a dividend?
Imunon does not currently pay a dividend.
When does Imunon next pay dividends?
Imunon does not currently pay a dividend.
How do I buy Imunon shares?
To buy shares in Imunon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Imunon?
As of the previous close price of $1.44, shares in Imunon had a market capitalisation of $13.54m.
Where are Imunon shares listed?
Here are the trading details for Imunon:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMNN
What kind of share is Imunon?
Based on an overall assessment of its quality, value and momentum Imunon is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Imunon share price forecast for 2024?
The analyst consensus target price for shares in Imunon is $12.00. That is 733.33% above the last closing price of $1.44.
Analysts covering Imunon currently have a consensus Earnings Per Share (EPS) forecast of -$2.27 for the next financial year.
What is the trend in the Imunon share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Imunon. Over the past six months, its share price has outperformed the S&P500 Index by +18.84%.
As of the last closing price of $1.44, shares in Imunon were trading +45.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Imunon PE Ratio?
The Imunon PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Imunon?
Imunon's management team is headed by:
- Jeffrey Church - CFO
- Khursheed Anwer - EVP
- Nicholas Borys - EVP
- Michael Tardugno - DRC
- Stacy Lindborg - DRC
- Christine Pellizzari - DRC
- Donald Braun - IND
- Augustine Chow - IND
- Frederick Fritz - IND
- Robert Hooper - IND